• Molecular NameMethyldopa
  • SynonymAlpha medopa; Alphamethyldopa; AMD; L-Methyl Dopa; Methyldopa anhydrous; Methyldopate; Methyldopate HCL; Mk; b51
  • Weight211.217
  • Drugbank_IDDB00968
  • ACS_NO555-30-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-2.26
  • pka2.2 (-COOH), 9.2 (-OH), 10.6(-NH2), 12.0 (-OH), (25°)
  • LogD (pH=7, predicted)-2.26
  • Solubility (experiment)10 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.65
  • LogSw (predicted, AB/LogsW2.0)4.26
  • Sw (mg/ml) (predicted, ACD/Labs)4.65
  • No.of HBond Donors5
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds3
  • TPSA103.78
  • StatusFDA approved
  • AdministrationOral, IV
  • PharmacologyA psychoactive drug used as a sympatholytic or antihypertensive. Its use is now deprecated following introduction of alternative safer classes of agents. However, it continues to have a role in otherwise difficult to treat hypertension and gestational hypertension (also known as pregnancy-induced hypertension (PIH)).
  • Absorption_value50.0
  • Absorption (description)Absorption from the gastrointestinal tract is variable but averages approximately 50%.
  • Caco_2N/A
  • Bioavailability35.0
  • Protein binding20.0
  • Volume of distribution (VD)0.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is metabolized in the liver
  • Half life2 h; a longer terminal elimination half-life has also been reported.
  • ExcretionRenal for metabolites
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
  • LD50 (rat)LD50>1.5 g/kg
  • LD50 (mouse)LD50>1.5 g/kg